Trial · NCT00728507

Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

NCT00728507, Phase 2, Terminated, Johns Hopkins University; results first posted 2017-04-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis. Trials, record NCT00728507. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00728507

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
NCT number: NCT00728507
Status: Terminated
Phases: Phase 2
Enrollment: 121 participants, actual
Lead sponsor: Johns Hopkins University
Conditions: Tuberculosis
Interventions: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid, Isoniazid, Rifampin, Pyrazinamide, Ethambutol
First posted: 2008-08-05
Last updated: 2017-04-20
Results first posted: 2017-04-20

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.	Week 8	LJ culture conversion
Primary	To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.	Weekly or more frequent	Study was prematurely terminated and data was not collected for this outcome measure.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.	Week 8	modified intention to treat population	percentage of participants	NUMBER
PRIMARY	To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.	Weekly or more frequent

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.	HPZM		78.3		percentage of participants
To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.	HRZE		84.3		percentage of participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	HPZM	62
Overall Study	STARTED	HRZE	59
Overall Study	COMPLETED	HPZM	60
Overall Study	COMPLETED	HRZE	51
Overall Study	NOT COMPLETED	HPZM	2
Overall Study	NOT COMPLETED	HRZE	8

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	flu-like syndrome	General disorders	HPZM	2	62
other	flu-like syndrome	General disorders	HRZE	0	59
other	change in visual refraction	Eye disorders	HPZM	2	62
other	change in visual refraction	Eye disorders	HRZE	1	59
other	rash	Skin and subcutaneous tissue disorders	HPZM	1	62
other	rash	Skin and subcutaneous tissue disorders	HRZE	0	59
other	anemia	Blood and lymphatic system disorders	HPZM	0	62
other	anemia	Blood and lymphatic system disorders	HRZE	1	59
other	nausea	Gastrointestinal disorders	HPZM	0	62
other	nausea	Gastrointestinal disorders	HRZE	1	59

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	HPZM
Total, all-cause mortality	HRZE
Total, other adverse events	HPZM	5	62
Total, other adverse events	HRZE	6	59
Total, serious adverse events	HPZM	0	62
Total, serious adverse events	HRZE	0	59

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
14578218	BACKGROUND	PubMed
15306535	BACKGROUND	PubMed
16574936	BACKGROUND	PubMed
27159505	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
HPZM vs HRZE: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00728507

GET https://conductscience.org/api/trials/v1/NCT00728507/registered

API reference For AI assistants